Generation Bio CO Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Atlas Venture entities report the disposal of all Generation Bio Co. common stock following the company's merger with XOMA Royalty Corporation's subsidiary.
Generation Bio Co. director Catherine Stehman-Breen disposed of common stock and options as the company became a wholly-owned subsidiary of XOMA Royalty Corporation following a merger.
Generation Bio Co. Director Charles A. Rowland Jr. disposed of common stock and stock options as part of the company's merger with XOMA Royalty Corporation.
Generation Bio Co. has been acquired by XOMA Royalty Corporation, with shareholders receiving cash and contingent value rights.
Anthony G. Quinn, a director at Generation Bio Co., reported the disposition of all his direct and indirect common stock and stock options following the company's merger with XOMA Royalty Corporation.
Generation Bio Co. director Donald William Nicholson reports the disposition of common stock and options following the company's merger with XOMA Royalty Corporation.
Generation Bio Co. Director Geoff McDonough reports the disposition of all common stock and cancellation of stock options following the company's merger with XOMA Royalty Corporation's subsidiary.
A Form 4 filing reveals Generation Bio Co. director Jeffrey M. Jonas's stock options were cancelled following the company's merger with XOMA Royalty Corporation.
Generation Bio Co.'s Interim CEO, Yalonda Howze, reports changes in beneficial ownership following the company's merger with XOMA Royalty Corporation.
Generation Bio Co. Director Ronald Cooper reported the disposition of all his common stock and stock options following the company's merger with XOMA Royalty Corporation, effective February 9, 2026.
Generation Bio Co. Chief Financial Officer Kevin John Conway's beneficial ownership of common stock and stock options was eliminated following the company's merger with XOMA Royalty Corporation.
Gustav Christensen, a director at Generation Bio Co., disposed of all his common stock and options following the company's acquisition by XOMA Royalty Corporation.
Generation Bio Co. director Dannielle Appelhans reported the disposition of common stock and stock options following the company's merger with XOMA Royalty Corporation's subsidiary.
Generation Bio Co.'s CFO, Kevin John Conway, reported the acquisition of common stock from restricted stock unit vesting and a subsequent disposition for tax purposes.
Generation Bio Co. Director Geoff McDonough reported future transactions involving the acquisition of common stock from restricted stock units and subsequent sale for tax obligations.
Generation Bio Co.'s Chief Legal Officer, Yalonda Howze, reported the exercise of restricted stock units and subsequent sale of shares for tax purposes.
Generation Bio Director Geoff McDonough reported stock transactions including RSU vesting acceleration and common stock acquisition and disposition following his resignation as CEO.
Phillip Samayoa will cease to be Generation Bio Co.'s Chief Scientific Officer and will no longer be subject to Section 16 reporting requirements as of October 31, 2025.
Antoinette Paone will step down as Chief Operating Officer of Generation Bio Co. effective October 31, 2025, ceasing Section 16 reporting obligations.
Generation Bio's Chief Scientific Officer, Phillip Samayoa, reported the scheduled vesting of restricted stock units and related common stock transactions.
Generation Bio Co. CEO Geoff McDonough reported the exercise of restricted stock units and subsequent sale of shares for tax obligations, reflecting a one-for-10 reverse stock split.
Generation Bio's Chief Legal Officer, Yalonda Howze, reported the acquisition and disposition of common stock following RSU vesting, reflecting a recent reverse stock split.
Generation Bio Co.'s Chief Operating Officer, Antoinette Paone, exercised restricted stock units and sold shares for tax withholding, adjusting her direct beneficial ownership.
Generation Bio Co.'s Chief Financial Officer, Kevin John Conway, reported the acquisition of common stock through restricted stock unit vesting and a subsequent disposition for tax obligations, reflecting a routine insider transaction.
Form 4: Generation Bio Chief Legal Officer Reports Routine RSU Vesting and Tax-Related Share Disposition
Generation Bio Co.'s Chief Legal Officer, Yalonda Howze, reported the vesting of restricted stock units and a subsequent disposition of shares for tax withholding purposes on July 15, 2025.
Generation Bio Co.'s Chief Financial Officer, Kevin John Conway, reported the acquisition of common stock through restricted stock unit vesting and subsequent disposition of shares for tax purposes on July 15, 2025.
Generation Bio Co.'s Chief Operating Officer, Antoinette Paone, reported the vesting and sale of common stock related to restricted stock units and shares acquired through an employee stock purchase plan.
Generation Bio Co.'s Chief Scientific Officer, Phillip Samayoa, converted 1,147 restricted stock units into common stock and subsequently disposed of 337 shares for tax purposes, resulting in a net increase of 810 directly held common shares.
Generation Bio Co. President and CEO Geoff McDonough disclosed recent stock acquisitions through Restricted Stock Unit vesting and dispositions for tax purposes, alongside updates to his beneficial ownership.
Generation Bio Co. Director Gustav Christensen has been granted 30,000 stock options with an exercise price of $0.3874, aligning his interests with shareholder value.